Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 2Glioblastoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × fotemustine × Clear all
NCT01359956 2023-04-11

SICOG 0109

National Cancer Institute, Naples

Phase 3 Completed
269 enrolled 12 charts
Dermatologic

Melanoma

NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 21 charts
Dermatologic

Melanoma

NCT01474239 2016-03-15

A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma

Hoffmann-La Roche

Phase 2 Completed
91 enrolled 19 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡